公开(公告)号：US08980878B2

公开(公告)日：2015-03-17

申请号：US13865069

申请日：2013-04-17

Applicant: Gilead Sciences, Inc.

Inventor： Dustin Siegel ,  David Sperandio ,  Hai Yang ,  Michael Sangi ,  Jay P. Parrish ,  Hon Chung Hui

IPC: A61K31/00 ,  C07D413/00

CPC classification number: C07D487/04 ,  A61K31/4545 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

Abstract translation: 提供了用于治疗病毒感染的化合物及其药学上可接受的盐和酯及其组合物。 化合物和组合物可用于治疗肺炎链球菌病毒感染。 提供的化合物，组合物和方法特别可用于治疗人呼吸道合胞病毒感染。

公开(公告)号：US08809330B2

公开(公告)日：2014-08-19

申请号：US14069685

申请日：2013-11-01

Applicant: Gilead Sciences, Inc.

Inventor： Kerim Babaoglu ,  Constantine G. Boojamra ,  Eugene J. Eisenberg ,  Hon Chung Hui ,  Richard L. Mackman ,  Jay P. Parrish ,  Michael Sangi ,  Oliver L. Saunders ,  Dustin Siegel ,  David Sperandio ,  Hai Yang

IPC: A61P31/14

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/675 ,  A61K45/06 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00 ,  C07F9/65616

Abstract: The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

Abstract translation: 本发明提供了本文所述的式I或式II化合物或其药学上可接受的盐或酯。 其化合物及其组合物可用于治疗肺炎链球菌病毒感染。 提供的化合物，组合物和方法特别可用于治疗人呼吸道合胞病毒感染。

公开(公告)号：US10174038B2

公开(公告)日：2019-01-08

申请号：US15618974

申请日：2017-06-09

Applicant: Gilead Sciences, Inc.

Inventor： Hon Chung Hui ,  Jay P. Parrish ,  Michael Sangi ,  Dustin Siegel ,  David Sperandio ,  Hai Yang

IPC: A61K31/397 ,  C07D487/04 ,  C07D519/00 ,  C07D471/04 ,  A61K45/06 ,  A61K31/4545 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377

Abstract: Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

公开(公告)号：US20170190708A1

公开(公告)日：2017-07-06

申请号：US15347494

申请日：2016-11-09

Applicant: Gilead Sciences, Inc.

Inventor： Kerim Babaoglu ,  Constantine G. Boojamra ,  Eugene J. Eisenberg ,  Hon Chung Hui ,  Richard L. Mackman ,  Jay P. Parrish ,  Michael Sangi ,  Oliver L. Saunders ,  Dustin Siegel ,  David Sperandio ,  Hai Yang

IPC: C07D487/04

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/675 ,  A61K45/06 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00 ,  C07F9/65616

Abstract: The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

公开(公告)号：US09655944B2

公开(公告)日：2017-05-23

申请号：US15185273

申请日：2016-06-17

Applicant: Gilead Sciences, Inc.

Inventor： Kyla Bjornson ,  Eda Canales ,  Jeromy J. Cottell ,  Kapil K. Karki ,  Ashley A. Katana ,  Darryl Kato ,  Tetsuya Kobayashi ,  John O. Link ,  Ruben Martinez ,  Barton W. Phillips ,  Hyung-jung Pyun ,  Michael Sangi ,  Adam J. Schrier ,  Dustin Siegel ,  James G. Taylor ,  Chinh V. Tran ,  Teresa A. Trejo Martin ,  Randall W. Vivian ,  Zheng-Yu Yang ,  Jeff Zablocki ,  Sheila Zipfel

IPC: A61K38/21 ,  A61K38/06 ,  C07D498/16 ,  A61K31/4985 ,  C07D498/22 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  C07K5/087 ,  C07K5/08 ,  C07K5/083 ,  A61K38/00

CPC classification number: A61K31/498 ,  A61K31/10 ,  A61K31/401 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K38/00 ,  A61K38/06 ,  A61K38/21 ,  A61K45/06 ,  C07D241/36 ,  C07D403/14 ,  C07D498/16 ,  C07D498/22 ,  C07K5/08 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/0827 ,  A61K2300/00

Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

公开(公告)号：US20150175655A1

公开(公告)日：2015-06-25

申请号：US14412331

申请日：2013-07-02

Applicant: Gilead Sciences, Inc.

Inventor： Kyla Bjornson ,  Eda Canales ,  Jeromy J. Cottell ,  Kapil Kumar Karki ,  Ashley Anne Katana ,  Darryl Kato ,  Tetsuya Kobayashi ,  John O. Link ,  Ruben Martinez ,  Barton W. Phillips ,  Hyung-Jung Pyun ,  Michael Sangi ,  Adam James Schrier ,  Dustin Siegel ,  James G. Taylor ,  Chinh Viet Tran ,  Teresa Alejandra Trejo Martin ,  Randall W. Vivian ,  Zheng-Yu Yang ,  Jeff Zablocki ,  Sheila Zipfel

IPC: C07K5/08 ,  A61K38/06 ,  A61K45/06

Abstract: Compounds of Formula I are disclosed, As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Abstract translation: 公开了式I的化合物，以及其药学上可接受的盐。 还公开了使用所述化合物和含有所述化合物的药物组合物的方法。

公开(公告)号：US20150038488A1

公开(公告)日：2015-02-05

申请号：US14448160

申请日：2014-07-31

Applicant: Gilead Sciences, Inc.

Inventor： Kevin S. Currie ,  Zhimin Du ,  Julie Farand ,  Juan A. Guerrero ,  Ashley A. Katana ,  Darryl Kato ,  Scott E. Lazerwith ,  Jiayao Li ,  John O. Link ,  Nicholas Mai ,  Gregory Notte ,  Hyung-Jung Pyun ,  Michael Sangi ,  Aaron C. Schmitt ,  Adam J. Schrier ,  Kirk L. Stevens ,  Chandrasekar Venkataramani ,  William J. Watkins ,  Zheng-Yu Yang ,  Jeff Zablocki ,  Sheila Zipfel

IPC: C07D487/04 ,  C07D417/04 ,  C07D417/12 ,  C07D403/12 ,  C07D471/04 ,  C07D401/14

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D519/00

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Abstract translation: 本公开涉及作为Syk抑制剂的化合物及其在治疗各种疾病状态（包括癌症和炎性病症）中的用途。 在具体实施方案中，化合物的结构由式I给出，其中X 1，X 2，X 3，R 2，R 3，R 4，R 5和Y如本文所述。 本公开进一步提供包含式I化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由Syk介导的病症的方法。

公开(公告)号：US20130164280A1

公开(公告)日：2013-06-27

申请号：US13722962

申请日：2012-12-20

Applicant: Gilead Sciences, Inc.

Inventor： Constantine G. Boojamra ,  Hon Chung Hui ,  Petr Jansa ,  Richard L. Mackman ,  Jay P. Parrish ,  Michael Sangi ,  Dustin Siegel ,  David Sperandio ,  Hai Yang

IPC: A61K45/06 ,  A61K31/519 ,  A61K31/675 ,  A61K31/538 ,  C07F9/6561 ,  C07D487/04 ,  C07D487/08

CPC classification number: A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/675 ,  A61K45/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00 ,  C07F9/6561

Abstract: The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.

公开(公告)号：US10005774B2

公开(公告)日：2018-06-26

申请号：US15150038

申请日：2016-05-09

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Jayaraman Chandrasekhar ,  Kevin S. Currie ,  Zhimin Du ,  Julie Farand ,  Juan A. Guerrero ,  Ashley A. Katana ,  Darryl Kato ,  Jeffrey E. Kropf ,  Scott E. Lazerwith ,  Seung H. Lee ,  Jiayao Li ,  John O. Link ,  Jennifer R. Lo ,  Nicholas Mai ,  Scott A. Mitchell ,  Gregory Notte ,  Hyung-jung Pyun ,  Michael Sangi ,  Aaron C. Schmitt ,  Adam J. Schrier ,  Kirk L. Stevens ,  Chandrasekar Venkataramani ,  William J. Watkins ,  Jin-Ming Xiong ,  Jianjun Xu ,  Zheng-Yu Yang ,  Jeff Zablocki ,  Zhongdong Zhao ,  Sheila Zipfel

IPC: C07D471/04 ,  C07D401/14 ,  C07D403/12 ,  C07D417/04 ,  C07D417/12 ,  C07D487/04 ,  C07D407/14 ,  C07D417/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D491/08 ,  C07D498/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D519/00

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

公开(公告)号：US20170362244A1

公开(公告)日：2017-12-21

申请号：US15639970

申请日：2017-06-30

Applicant: Gilead Sciences, Inc.

Inventor： Kerim Babaoglu ,  Constantine G. Boojamra ,  Eugene J. Eisenberg ,  Hon Chung Hui ,  Richard L. Mackman ,  Jay P. Parrish ,  Michael Sangi ,  Oliver L. Saunders ,  Dustin Siegel ,  David Sperandio ,  Hai Yang

IPC: C07D487/04 ,  C07D519/00 ,  C07D513/04 ,  C07D495/04 ,  A61K45/06 ,  A61K31/675 ,  A61K31/551 ,  A61K31/55 ,  A61K31/5377 ,  C07F9/6561 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/675 ,  A61K45/06 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00 ,  C07F9/65616

Abstract: The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.